Australian Public Assessment Report for Adalimumab

Proprietary Product Name: Humira

Sponsor: Abbott Australasia Pty Ltd (AbbVie Pty Ltd)

January 2014
About the Therapeutic Goods Administration (TGA)

- The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices.

- The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary.

- The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices.

- The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action.

- To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>.

About AusPARs

- An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.

- AusPARs are prepared and published by the TGA.

- An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications.

- An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time.

- A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.

Copyright

© Commonwealth of Australia 2014

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>. 
Contents

List of abbreviations __________________________________________________________ 4
I. Introduction to product submission _____________________________________ 8
   Submission details ________________________________________________________ 8
   Product background ____________________________________________________________________ 8
   Regulatory status _____________________________________________________________________ 9
   Product Information_________________________________________________________________ 10
II. Quality findings ___________________________________________________________ 10
III. Nonclinical findings _____________________________________________________ 10
IV. Clinical findings __________________________________________________________ 10
   Introduction __________________________________________________________________________ 10
   Pharmacokinetics ____________________________________________________________________ 11
   Pharmacodynamics ____________________________________________________________________ 11
   Efficacy _______________________________________________________________________________ 11
   Safety _________________________________________________________________________________ 13
   First round benefit-risk assessment _______________________________________________ 14
   First round recommendation regarding authorisation __________________________ 15
   List of questions _____________________________________________________________________ 15
   Second round evaluation of clinical data submitted in response to questions _ 15
   Second round recommendation regarding authorisation________________________ 15
V. Pharmacovigilance findings ____________________________________________ 16
   Risk management plan ____________________________________________________________ 16
VI. Overall conclusion and risk/benefit assessment __________________ 20
   Quality ________________________________________________________________________________ 20
   Nondclinical ___________________________________________________________________________ 21
   Clinical ________________________________________________________________________________ 21
   Risk management plan ______________________________________________________________ 23
   Risk-benefit analysis ________________________________________________________________ 23
   Outcome ______________________________________________________________________________ 31
Attachment 1. Product Information ____________________________________ 31
Attachment 2. Extract from the Clinical Evaluation Report ______ 31
# List of abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>ALS</td>
<td>Amyotrophic lateral sclerosis</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine transaminase</td>
</tr>
<tr>
<td>ANA</td>
<td>Anti-nuclear antibody</td>
</tr>
<tr>
<td>AP</td>
<td>Antero-posterior</td>
</tr>
<tr>
<td>AS</td>
<td>Ankylosing spondylitis</td>
</tr>
<tr>
<td>ASAS</td>
<td>Assessments in Spondyloarthritis International Society</td>
</tr>
<tr>
<td>ASDAS</td>
<td>Ankylosing Spondylitis Disease Activity Score</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate transaminase</td>
</tr>
<tr>
<td>BASDAI</td>
<td>Bath Ankylosing Spondylitis disease activity index</td>
</tr>
<tr>
<td>BASFI</td>
<td>Bath Ankylosing Spondylitis functional index</td>
</tr>
<tr>
<td>BASMI</td>
<td>Bath Ankylosing Spondylitis Metrology Index</td>
</tr>
<tr>
<td>BCG</td>
<td>Bacille Calmette-Guérin</td>
</tr>
<tr>
<td>BUN</td>
<td>Blood urea nitrogen</td>
</tr>
<tr>
<td>CD</td>
<td>Crohn's disease</td>
</tr>
<tr>
<td>CDC</td>
<td>Centers for Disease Control</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>CRP</td>
<td>C-reactive protein</td>
</tr>
<tr>
<td>CSR</td>
<td>Clinical study report</td>
</tr>
<tr>
<td>CTC</td>
<td>Common toxicity criteria</td>
</tr>
<tr>
<td>CTCAE</td>
<td>Common Terminology Criteria for Adverse Events</td>
</tr>
<tr>
<td>CTX-II</td>
<td>Type II collagen C-telopeptide</td>
</tr>
<tr>
<td>CVA</td>
<td>Cerebrovascular accident</td>
</tr>
<tr>
<td>CXR</td>
<td>Chest x-ray</td>
</tr>
<tr>
<td>DAE</td>
<td>Discontinuation due to adverse event</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>DB</td>
<td>Double-blind</td>
</tr>
<tr>
<td>DMARD</td>
<td>Disease-modifying anti-rheumatic drugs</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>eow</td>
<td>Every other week</td>
</tr>
<tr>
<td>EQ-5D</td>
<td>European Quality of Life – 5 Dimensions questionnaire</td>
</tr>
<tr>
<td>F</td>
<td>Female</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>FDA</td>
<td>Food and Drug Administration</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>HAQ-S</td>
<td>Health Assessment Questionnaire modified for spondyloarthropathies</td>
</tr>
<tr>
<td>HCP</td>
<td>Health care provider</td>
</tr>
<tr>
<td>HCRU</td>
<td>Health care resource utilization</td>
</tr>
<tr>
<td>HLA-B27</td>
<td>Human leukocyte antigen-B27</td>
</tr>
<tr>
<td>hs-CRP</td>
<td>High sensitivity C-reactive protein</td>
</tr>
<tr>
<td>HSTCL</td>
<td>Hepatosplenic T-cell lymphoma</td>
</tr>
<tr>
<td>IBD</td>
<td>Inflammatory bowel disease</td>
</tr>
<tr>
<td>ICF</td>
<td>Informed consent form</td>
</tr>
<tr>
<td>ICH</td>
<td>International Conference on Harmonisation</td>
</tr>
<tr>
<td>IEC</td>
<td>Independent ethics committee</td>
</tr>
<tr>
<td>IRB</td>
<td>Institutional review board</td>
</tr>
<tr>
<td>ITT</td>
<td>Intent-to-treat</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>IWRS</td>
<td>Interactive web response system</td>
</tr>
<tr>
<td>LOCF</td>
<td>Last observation carried forward</td>
</tr>
<tr>
<td>LFT</td>
<td>Liver function test</td>
</tr>
<tr>
<td>M</td>
<td>Male</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>MASES</td>
<td>Maastricht Ankylosing Spondylitis Enthesitis Score</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical Dictionary for Regulatory Activities</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial infarction</td>
</tr>
<tr>
<td>MMP-3</td>
<td>Matrix metalloproteinase 3</td>
</tr>
<tr>
<td>MOS</td>
<td>Medical outcomes study</td>
</tr>
<tr>
<td>MRI</td>
<td>Magnetic resonance imaging</td>
</tr>
<tr>
<td>MTX</td>
<td>Methotrexate</td>
</tr>
<tr>
<td>NMSC</td>
<td>Non-melanoma skin cancer</td>
</tr>
<tr>
<td>nr-axSpA</td>
<td>Non-radiographic axial SpA</td>
</tr>
<tr>
<td>NRI</td>
<td>Non-responder imputation</td>
</tr>
<tr>
<td>NSAID</td>
<td>Nonsteroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York Heart Association</td>
</tr>
<tr>
<td>OC</td>
<td>Observed case</td>
</tr>
<tr>
<td>OL</td>
<td>Open-label</td>
</tr>
<tr>
<td>PA</td>
<td>Posterior-anterior</td>
</tr>
<tr>
<td>PASS</td>
<td>Patient acceptable symptom state</td>
</tr>
<tr>
<td>PGA</td>
<td>Physician's Global Assessment of Disease Activity</td>
</tr>
<tr>
<td>PML</td>
<td>Progressive multifocal leukoencephalopathy</td>
</tr>
<tr>
<td>POR</td>
<td>Proof of receipt</td>
</tr>
<tr>
<td>PPD</td>
<td>Purified protein derivative</td>
</tr>
<tr>
<td>PPP</td>
<td>Per-protocol population</td>
</tr>
<tr>
<td>Ps</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>PsA</td>
<td>Psoriatic arthritis</td>
</tr>
<tr>
<td>PT</td>
<td>Preferred term</td>
</tr>
<tr>
<td>PTGA</td>
<td>Patient's Global Assessment</td>
</tr>
<tr>
<td>PY</td>
<td>Patient-year</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cell</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Meaning</td>
</tr>
<tr>
<td>--------------</td>
<td>---------</td>
</tr>
<tr>
<td>RPLS</td>
<td>Reversible posterior leukoencephalopathy syndrome</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical analysis plan</td>
</tr>
<tr>
<td>SC</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>SF-36™V2</td>
<td>Short Form-36 Health Status Survey™ Version 2</td>
</tr>
<tr>
<td>SGOT</td>
<td>Serum glutamic-oxaloacetic transaminase</td>
</tr>
<tr>
<td>SGPT</td>
<td>Serum glutamic-pyruvic transaminase</td>
</tr>
<tr>
<td>SJC</td>
<td>Swollen joint count</td>
</tr>
<tr>
<td>SOC</td>
<td>System organ class</td>
</tr>
<tr>
<td>SpA</td>
<td>Spondyloarthritis</td>
</tr>
<tr>
<td>SPARCC</td>
<td>Spondyloarthritis Research Consortium of Canada</td>
</tr>
<tr>
<td>SSZ</td>
<td>Sulfasalazine</td>
</tr>
<tr>
<td>TB</td>
<td>Tuberculosis</td>
</tr>
<tr>
<td>TEAE</td>
<td>Treatment-emergent adverse event</td>
</tr>
<tr>
<td>TJC</td>
<td>Tender joint count</td>
</tr>
<tr>
<td>TNF</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>UC</td>
<td>Ulcerative colitis</td>
</tr>
<tr>
<td>ULN</td>
<td>Upper limit of normal</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>VAS</td>
<td>Visual analog scale</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cell</td>
</tr>
<tr>
<td>WPAI-SHP</td>
<td>Work Productivity and Activity Impairment – Specific Health Problem Questionnaire</td>
</tr>
<tr>
<td>VEGF&lt;sub&gt;A&lt;/sub&gt;</td>
<td>Vascular endothelial growth factor A</td>
</tr>
</tbody>
</table>
I. Introduction to product submission

Submission details

Type of submission: Extension of indications
Decision: Withdrawn
Date of decision: 19 August 2013
Active ingredient: Adalimumab
Product name: Humira
Sponsor’s name and address: AbbVie Pty Ltd
32-34 Lord Street
Botany NSW 2019
Dose form: Solution for Injection
Strengths: 20 mg and 40 mg
Container: Pre-filled syringe, vial and pen (latter two in 40 mg only).
Approved therapeutic use: Not applicable
Route of administration: Subcutaneously
Dosage: Non-radiographic Axial Spondyloarthritis: 40 mg fortnightly
ARTG number: Not applicable

Product background

Humira (adalimumab) is a Tumour necrosis factor (TNF)–α neutralising recombinant immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. It binds to TNF and neutralises the biological function of TNF by blocking its interaction with the p55 and p75 cell surface receptors. Humira is produced by recombinant deoxyribonucleic acid (DNA) technology in a mammalian cell expression system.

This AusPAR describes the application by the sponsor to extend the indications for Humira (adalimumab) for:

Non-radiographic Axial Spondyloarthritis (axial spondyloarthritis without radiographic evidence of AS): Humira is indicated for reducing signs and symptoms in patients with non-radiographic axial spondyloarthritis.

Adalimumab has been previously considered by the TGA on numerous occasions, with the ankylosing spondylitis (AS) indication considered in June 2006.

The sponsor has explained the rationale for this indication as follows:

“Currently, there is an unmet medical need in patients with nr-axSpA who have disease features similar to patients with Ankylosing Spondylitis (AS), but who do not fulfil the modified New York criteria for AS by virtue of not having evidence of structural damage in the form of radiographic sacroiliitis. Not all patients with nr-
AxSpA go on to develop radiographic sacroiliitis required to fulfill the modified New York criteria for a diagnosis of AS. While non-steroidal anti-inflammatory drugs (NSAIDs) are effective in treating the signs and symptoms of axial SpA in some patients, traditional anti-rheumatic therapies such as methotrexate and sulfasalazine are not effective for the axial component of spondyloarthritis and the use of systemic corticosteroids is not supported by evidence. The potential benefit of anti-TNF therapy in nr-axSpA has been acknowledged by the Assessments in Spondyloarthritis International Society (ASAS) working group that recently published their recommendations for the use of anti-TNF in axial SpA patients. This working group has proposed and validated new classification criteria for patients with axial SpA. Abbott has used this published ASAS criteria to classify nr-axSpA patients for the pivotal study.”

Regulatory status

Adalimumab was first approved in Australia in 2003 for rheumatoid arthritis and is currently approved for use in a variety of conditions including psoriatic arthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, psoriasis and Crohn’s disease.1

Adalimumab has been approved for a modified indication in the European Union (EU) under the Centralised Procedure (July 2012).

The submission is currently under evaluation in Canada, USA, Switzerland and New Zealand.

The data submitted to the TGA was the same as that submitted in the EU. The approved indication in the EU has also been combined with the AS indication under a new heading called Axial Spondyloarthritis as follows:

**Axial spondyloarthritis**

**Ankylosing spondylitis (AS)**

*Humira is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.*

**Axial spondyloarthritis without radiographic evidence of AS.**

---

1 Currently approved indications:

**Rheumatoid Arthritis:** Humira is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adults with moderate to severely active rheumatoid arthritis. This includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate.

*Humira can be used alone or in combination with methotrexate.*

**Psoriatic Arthritis:** Humira is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous DMARDs has been inadequate.

**Ankylosing Spondylitis:** Humira is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

**Crohn’s Disease:** Humira is indicated for the treatment of moderate to severe Crohn’s disease in adults to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients who have had an inadequate response to conventional therapies, or who have lost response to or are intolerant of infliximab.

**Psoriasis:** Humira is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

**Polyarticular Juvenile Idiopathic Arthritis:** Humira in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 4 years of age and older.

*Humira can be given as monotherapy in case of intolerance or when continued treatment with methotrexate is inappropriate.*
**Product Information**

The approved Product Information (PI) current at the time this AusPAR was prepared can be found as Attachment 1.

**II. Quality findings**

There was no requirement for a quality evaluation in a submission of this type.

**III. Nonclinical findings**

There was no requirement for a nonclinical evaluation in a submission of this type.

**IV. Clinical findings**

A summary of the clinical findings is presented in this section. Further details of these clinical findings can be found in Attachment 2.

**Introduction**

**Clinical rationale**

The sponsor justified the development of adalimumab for the treatment of non-radiographic Axial Spondyloarthritis (nr-axSpA) with the following argument:

"Currently, there is an unmet medical need in patients with nr-axSpA who have disease features similar to patients with Ankylosing Spondylitis (AS), but who do not fulfil the modified New York criteria for AS by virtue of not having evidence of structural damage in the form of radiographic sacroiliitis."

This patient group does not respond to traditional Disease-modifying anti-rheumatic drugs (DMARDs) such as Methotrexate (MTX) and sulfasalazine. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide some symptom relief but some patients may not have sufficient response to this treatment. Whilst adalimumab and other anti-TNF therapies have been approved for the indication of Ankylosing spondylitis (AS), patients with nr-axSpA do not have access to (approved) treatments other than NSAIDs.

**Contents of the clinical dossier**

The submission contained the following clinical information:

- One efficacy/safety study: Study M 10-791.
- Three files containing tabulations of pooled safety data
Paediatric data

The submission did not include paediatric data. There are no plans for a paediatric development program for non radiographic axial spondyloarthritis (nr-axSpA).

Good clinical practice

The studies presented in the present application were conducted in accordance with Good Clinical Practice.

Pharmacokinetics

There were no new pharmacokinetic data included in the dossier.

Pharmacodynamics

There were no new pharmacodynamic data included in the dossier.

Efficacy

Dosage selection for the pivotal studies

The sponsor did not conduct dose finding studies for the present application. The dose selected for development appears to be based on the approved dose for the indication of AS.

Evaluator’s conclusions on clinical efficacy for Non-Radiographic Axial SpA

Efficacy has been demonstrated for adalimumab in comparison with placebo for the indication of nr-axSpA over a 12 week period. The response rate was both clinically and statistically significant. The response was maintained in an open label follow-on study for up to 68 weeks. Response was greater in subjects with elevated C-reactive protein (CRP) at baseline and with shorter duration of symptoms. For those subjects with no concomitant Disease-modifying anti-rheumatic drugs (DMARDs) at baseline (monotherapy) there were five (26.3%) responders in the adalimumab group and none in the placebo.

The Assessments in Spondyloarthritis International Society (ASAS) worked on developing criteria for axial Spondyloarthritis (SpA) that include patients with and without definite radiographic sacroiliitis because "radiographic changes may reflect the consequences of inflammation (structural damage) rather than inflammation itself, which may be readily detectable by magnetic resonance imaging (MRI), often years before the appearance of radiographic sacroiliitis". These criteria were developed using questionnaires, logistic regression, sensitivity and specificity analysis and were voted on by the members of the ASAS (Figure 1).

Radiographic axial SpA is currently an indication for adalimumab but non-radiographic axial SpA is currently not an indication. In order to demonstrate the efficacy and safety of adalimumab in non-radiographic axial SpA subjects with Ankylosing spondylitis (AS), Psoriatic arthritis (PsA) and rheumatoid arthritis (RA) (all current indications) needed to be excluded from the study population. The inclusion criteria and exclusion criteria satisfactorily define the study population (and this study population is the same as that intended for treatment).

The indication of nr-axSpA could be considered to be an extension of AS, which is currently an approved indication for adalimumab. This supports the dose regimen chosen for development for nr-axSpA.

The primary efficacy outcome measure was ASAS40 response. This measure was a previously validated outcome measure and was developed independent of the development program. There were a large number of secondary outcome measures, all of which can be rationally applied to nr-axSpA. All of these outcome measures were supportive of efficacy compared with placebo over 12 weeks and maintenance of efficacy for up to 68 weeks.

The limitations of the efficacy data include:

- Few elderly subjects were included in Study M10-791 (only two subjects over the age of 65 years)
- There were no analyses to investigate drug-drug or drug-disease interactions; and drug dose, drug concentration, and relationship to response.
- Nr-axSpA is a chronic condition and there were no efficacy data extending beyond 68 weeks.

---

3 ASAS 40 is defined as at least a 40 percent improvement from baseline using the ASAS criteria.
Safety

Studies providing evaluable safety data
Study M10-791 provided evaluable safety data for this submission.

The sponsor provided some summary tables of safety data across all clinical trials of adalimumab. These tables relate to proposed changes in Product Information document for event rates for infection, malignancy and withdrawal due to adverse events (AEs). These rates have been adjusted to include data for the indication of nr-axSpA. The rates presented in the draft PI do correspond with those presented in the tabulations.

Pivotal studies that assessed safety as a primary outcome
There were no additional pivotal studies that assessed safety as a primary outcome.

Patient exposure
In Study M10-791, there were 190 subjects exposed to adalimumab, of whom 164 (86.3%) were exposed for ≥175 days, 147 (77.4%) were exposed for ≥343 days and 69 (36.3%) for ≥427 days. Total patient-years exposure was 193.3 years.

Postmarketing experience
No postmarketing data were included in the submission.

Evaluator’s overall conclusions on clinical safety
Exposure to adalimumab for the indication of nr-axSpA is limited, with total exposure being 190 subjects of whom 147 were exposed for ≥343 days and total patient-years exposure was 193.3 years.

The rate of TEAEs during the 12 week double blind phase was similar to that for placebo. The rate of infections was similar to that for placebo. Injection site related AEs were more common with adalimumab than placebo: 8.4% subjects compared with 3.1% respectively. These injection site reactions were mild in nature. Allergic reactions were more common with adalimumab than placebo: nine (4.7%) subjects compared with one respectively. The rate of SAEs was similar for the two treatment groups. The rate of DAE was similar for the two treatment groups.

Overall, in those subjects exposed to adalimumab the profile of AEs was similar to that previously reported for adalimumab. There were three subjects with serious infectious AEs, one of which was Tuberculosis (TB). There were no reports of opportunistic infections (excluding TB), lymphomas, Non-melanoma skin cancer (NMSC), malignancies (excluding NMSC and lymphomas) or demyelinating disease.

There were two deaths during the study, neither of which appeared to be related to study treatment.

There were no new safety concerns apparent in the clinical data.

There were no indications of drug interactions, or of concomitant medication (including DMARDs) contributing to an increased risk of AEs.

The safety data is limited by the relatively small number of subjects exposed to adalimumab of the indication of nr-axSpA. However, the indication is similar to AS, and the patient group studied similar to others previously studied for other indications that adalimumab is already approved for. Hence, the adverse effects profile of adalimumab for the indication of nr-axSpA can be expected to be the same as that for the previously approved indications.
**First round benefit-risk assessment**

**First round assessment of benefits**

Efficacy has been demonstrated for adalimumab in comparison with placebo for the indication of nr-axSpA over a 12 week period. The response rate was both clinically and statistically significant. The response was maintained in an open label follow-on study for up to 68 weeks. Response was greater in subjects with elevated CRP at baseline and with shorter duration of symptoms. For those subjects with no concomitant DMARDs at baseline (monotherapy) there were five (26.3%) responders in the adalimumab group and none in the placebo.

The indication of nr-axSpA could be considered to be an extension of AS, which is currently an approved indication for adalimumab. This supports the dose regimen chosen for development for nr-axSpA.

The primary efficacy outcome measure was ASAS40 response. This measure was a previously validated outcome measure and was developed independent of the development program. There were a large number of secondary outcome measures, all of which can be rationally applied to nr-axSpA. All of these outcome measures were supportive of efficacy compared with placebo over 12 weeks, and maintenance of efficacy for up to 68 weeks.

The limitations of the efficacy data include:

- Few elderly subjects were included in Study M10-791 (only two subjects over the age of 65 years)
- There were no analyses to investigate drug-drug or drug-disease interactions; and drug dose, drug concentration and relationship to response.
- Nr-axSpA is a chronic condition and there were no efficacy data extending beyond 68 weeks.

**First round assessment of risks**

Exposure to adalimumab for the indication of nr-axSpA is limited, with total exposure being 190 subjects of whom 147 were exposed for ≥343 days and total patient-years exposure was 193.3 years.

The rate of treatment emergent AEs (TEAEs) during the 12 week double blind phase was similar to that for placebo. The rate of infections was similar to that for placebo. Injection site related AEs were more common with adalimumab than placebo: 8.4% subjects compared with 3.1% respectively. These injection site reactions were mild in nature. Allergic reactions were more common with adalimumab than placebo: nine (4.7%) subjects compared with one respectively. The rate of serious AEs (SAEs) was similar for the two treatment groups. The rate of Discontinuation due to adverse event (DAE) was similar for the two treatment groups.

Overall, in those subjects exposed to adalimumab the profile of AEs was similar to that previously reported for adalimumab. There were three subjects with serious infectious AEs, one of which was TB. There were no reports of opportunistic infections (excluding TB), lymphomas, NMSC, malignancies (excluding NMSC and lymphomas) or demyelinating disease.

There were two deaths during the study, neither of which appeared to be related to study treatment.

There were no new safety concerns apparent in the clinical data.
There were no indications of drug interactions or of concomitant medication (including DMARDs) contributing to an increased risk of AEs.

The safety data is limited by the relatively small number of subjects exposed to adalimumab of the indication of nr-axSpA. However, the indication is similar to AS and the patient group studied similar to others previously studied for other indications that adalimumab is already approved for. Hence, the adverse effects profile of adalimumab for the indication of nr-axSpA can be expected to be the same as that for the previously approved indications.

First round assessment of benefit-risk balance
The benefit-risk balance of adalimumab, given the proposed usage, was considered to be favourable.

First round recommendation regarding authorisation
The evaluator recommended that adalimumab should be approved for the additional indication of:

**Non-Radiographic Axial Spondyloarthritis**
*Humira is indicated for reducing signs and symptoms in patients with non-radiographic axial spondyloarthritis*

List of questions
The only questions raised by the evaluator concerned the draft Product Information document and discussion of these issues are beyond the scope of this AusPAR.

Second round evaluation of clinical data submitted in response to questions

Second round benefit-risk assessment

Second round assessment of benefits
After consideration of the responses to clinical questions, the benefits of adalimumab in the proposed usage were considered to be unchanged from those identified in the First Round Evaluation.

Second round assessment of risks
After consideration of the responses to clinical questions, the risks of adalimumab in the proposed usage were considered to be unchanged from those identified in the First Round Evaluation.

Second round assessment of benefit-risk balance
The benefit-risk balance of adalimumab, given the proposed usage, was considered to be favourable.

Second round recommendation regarding authorisation
The evaluator recommended that adalimumab should be approved for the additional indication of:
Non-Radiographic Axial Spondyloarthritis

Humira is indicated for reducing signs and symptoms in patients with non-radiographic axial spondyloarthritis

V. Pharmacovigilance findings

Risk management plan
The sponsor submitted a Risk Management Plan which was reviewed by the TGA’s Office of Product Review (OPR).

Safety specification
The sponsor provided a summary of Ongoing Safety Concerns which are shown in Table 1.

Table 1. Summary of Ongoing Safety Concerns. Table continued across 3 pages.

<table>
<thead>
<tr>
<th>Important identified risks</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Serious infections including opportunistic infections, for example, invasive fungal infections, parasitic infections, legionellosis, and TB</td>
</tr>
<tr>
<td>• Reactivation of hepatitis B</td>
</tr>
<tr>
<td>• Pancreatitis</td>
</tr>
<tr>
<td>• Lymphoma</td>
</tr>
<tr>
<td>• Hepatosplenic T-cell Lymphoma</td>
</tr>
<tr>
<td>• Leukemia</td>
</tr>
<tr>
<td>• Non-melanoma Skin Cancer</td>
</tr>
<tr>
<td>• Melanoma</td>
</tr>
<tr>
<td>• Demyelinating disorders (including MS, GBS, and optic neuritis)</td>
</tr>
<tr>
<td>• Immune reactions (including lupus-like reactions and allergic reactions)</td>
</tr>
<tr>
<td>• Sarcoidosis</td>
</tr>
<tr>
<td>• Congestive Heart Failure</td>
</tr>
<tr>
<td>• Myocardial Infarction</td>
</tr>
<tr>
<td>• Cerebrovascular Accident</td>
</tr>
<tr>
<td>• Interstitial Lung Disease</td>
</tr>
<tr>
<td>• Pulmonary embolism</td>
</tr>
<tr>
<td>• Cutaneous vasculitis</td>
</tr>
<tr>
<td>• SJS and erythema multiforme</td>
</tr>
<tr>
<td>• Worsening and new onset of Ps</td>
</tr>
<tr>
<td>• Haematologic disorders</td>
</tr>
<tr>
<td>• Intestinal perforation</td>
</tr>
</tbody>
</table>
### Summary of ongoing safety concerns

- Intestinal strictures in CD
- Liver failure
- Elevated ALT levels
- Medication errors and maladministration

### Important potential risks

- Other malignancies (except lymphoma, HSTCL, leukemia, NMSC and melanoma)
- Vasculitis (non-cutaneous)
- Progressive Multifocal Leukoencephalopathy
- Reversible Posterior Leukoencephalopathy Syndrome
- Amyotrophic Lateral Sclerosis
- Colon cancer in UC patients
- Infections in infants exposed to adalimumab *in utero*
- Medication errors with paediatric vial
- Off-label use

### Important missing information

- Subjects with immune-compromised conditions (i.e., subjects with HIV, post-chemotherapy, organ transplant)
- Subjects with a history of clinically significant drug or alcohol abuse
- Subjects with poorly controlled medical conditions such as uncontrolled diabetes or documented history of recurrent infections, unstable ischemic heart disease, CHF, recent cerebrovascular accidents
- Subjects with history of listeriosis, history of histoplasmosis, active TB, persistent chronic or active infections requiring treatment with antibiotics, antivirals, or antifungals, history of viral hepatitis
- Subjects with history of cancer, lymphoma, leukaemia, or lymphoproliferative disease;
- Subjects with history of neurologic symptoms suggestive of demyelinating disorders
- Children < 18 years of age for PsA, AS, Ps, UC, SpA, HS, ERA, and uveitis indications
- Children < 4 years of age for JIA and pedPs
- Children < 6 years of age for pedCD and pedERA
- Pregnant and lactating women
- Subjects with renal or liver impairment
- Patients taking concomitant biologic therapy
- Long-term RA data beyond 5 years
## Summary of ongoing safety concerns

| Long-term JIA data beyond 7.5 years |
| Episodic treatment in JIA |
| Long-term AS data beyond 5 years |
| Short- and long-term SpA data |
| Short- and long-term pedERA data |
| Long-term PsA data beyond 3 years |
| Long-term Ps data beyond 6 years |
| Episodic treatment in Ps |
| Short- and long-term HS data |
| Long-term CD data beyond 5 years |
| Episodic treatment in CD |
| Long-term ped CD data beyond 2 years |
| Long-term UC data |
| Episodic treatment in UC; |
| Short- and long-term uveitis data. |

RA= Rheumatoid Arthritis; JIA= Polyarticular juvenile idiopathic arthritis PsA= Psoriatic arthritis; AS= Ankylosing spondylitis CD= Crohn’s disease; Ps =Psoriasis; pedERA= Paediatric Enthesitis-related Arthritis; SpA= Spondyloarthritis; UC= Ulcerative Colitis

### Evaluator comment

Notwithstanding the clinical and nonclinical evaluations, it was considered that the list of Ongoing Safety concerns was acceptable.

### Pharmacovigilance plan

Routine pharmacovigilance was proposed by the sponsor for all Important identified and potential risks. Routine activities, as described by the sponsor include monitoring through long term clinical studies, registries and postmarketing surveillance activities.

There are multiple ongoing pharmacovigilance activities which apply to the other approved indications. For the purposes of this report the activities relating to the proposed application are described below.

- **M10-791** is a 12 week randomised, double-blind, placebo controlled study to assess the efficacy and safety of adalimumab in subjects with axial spondyloarthritis followed by a 92 week open-label period. 192 subjects are enrolled and Australian patients are included. Interim data from this study (up to 68 weeks) was included as a pivotal study in this application.

- **M10-883** is a 12 week randomised double-blind placebo controlled study to assess the efficacy and safety of adalimumab in the treatment of adult subjects with non-AS, non-PsA active peripheral spondyloarthritis. An open label period of this study will continue for 92 weeks. 73 subjects are enrolled and Australian patients are included. As these studies were ongoing at the time of this report, the protocols have not been evaluated in detail for the purposes of this evaluation. Nevertheless it was expected

---

4 Sponsor comment: “Since the publication of this RMP, the protocols for these studies have been amended to include a 144 week open-label extension.”
that results of these studies will be communicated to the TGA via Periodic Safety Update Reports (PSURs) and updates to the RMP.

Risk minimisation activities

The sponsor stated that routine risk minimisation activities are not sufficient for the following safety concerns: serious infections, lymphoma, Hepatosplenic T-cell lymphoma (HSTCL), leukemia, NMSC, melanoma, demyelinating disorders, Congestive heart failure (CHF), medication errors and maladministration, other malignancies. For these safety concerns, an educational program was proposed as additional risk minimisation. According to the RMP the program comprises the following elements:

- Patient Information Alert Card
- Humira safety monograph
- TB screening brochure
- TB screening checklist
- Publications on specific safety topics

In regard to routine risk minimisation the draft Product Information and Consumer Medicine Information were considered to be satisfactory.

The following table (Table 2) summarises the OPR’s evaluation of the RMP, the sponsor’s responses to issues raised by the OPR and the second round OPR evaluation of the sponsor’s responses.

Table 2. Reconciliation of issues outlined in the RMP report. Continued across 2 pages.

<table>
<thead>
<tr>
<th>Recommendation in RMP evaluation report</th>
<th>Sponsor’s response</th>
<th>OPR evaluator’s comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Safety considerations may be raised by the clinical and non-clinical evaluators through the TGA's consolidated requests and/or the nonclinical and clinical Evaluation Reports respectively. It is important to ensure that the information provided in response to these includes consideration of the relevance for the Risk Management Plan and any specific information needed to address this issue in the RMP. For any safety considerations so raised, please provide information that is relevant and necessary to address the issue in the RMP.</td>
<td>The safety profile of adalimumab is well established and no safety issues requiring further consideration were raised in the TGA’s consolidated request for information. AbbVie has not yet received a copy of the clinical evaluation report.</td>
<td>This was considered acceptable.</td>
</tr>
<tr>
<td>2. The sponsor should provide further detail of the education program for Australia including whether it is already in use, draft education materials and a distribution plan.</td>
<td>The sponsor has provided further detail and draft versions of the educational materials.</td>
<td>The current and planned activities as outlined in the sponsor’s response were acceptable from a RMP standpoint. Such detail should be included in the Australian-specific Annex when it is next updated</td>
</tr>
</tbody>
</table>
It was considered that the sponsor’s response to the TGA consolidated request for information adequately addressed all of the issues identified in the RMP evaluation report.

**Outstanding issues**

There were no outstanding issues in relation to the RMP for this submission.

**Advice from the Advisory Committee on the Safety of Medicines (ACSOM)**

ACSOM advice was not sought for this submission.

**Suggested wording for conditions of registration**

**RMP**

Implement RMP for Adalimumab (Edition 10.0, November 2011) with Australian Specific Annex (undated) and any future updates as a condition of registration.

**PSUR**

Note: In the EU, PSURs are required every 3 years for this product.

**VI. Overall conclusion and risk/benefit assessment**

The submission was summarised in the following Delegate’s overview and recommendations:

**Quality**

There was no requirement for a quality evaluation in a submission of this type.
Nonclinical

There was no requirement for a nonclinical evaluation in a submission of this type.

Clinical

The clinical evaluator has reviewed the submitted data, which included:

- 1 Phase III pivotal study (Study M10-791).
- 3 reports of analyses on infections/Infestations, non-infection and Humira SpA Label support.

The clinical evaluator recommended approval in the evaluation report for the indication as requested by the sponsor with no changes requested for the PI.

The benefits noted by the evaluator included:

- Clinically and statistically significant efficacy over a 12 week period compared to placebo.
- Maintenance of efficacy in an open label follow-up.
- Response was greater in those with elevated CRP at baseline and shorter duration of symptoms.
- Safety profile was consistent with previously reported studies and no new safety concerns.

The concerns or issues noted by the evaluator included:

- Few elderly subjects were included in the pivotal trial (only two over 65 years).
- No analyses of drug-drug or drug-disease interactions and relationship to response.
- No efficacy data beyond 68 weeks.
- Safety data is limited but the indication is similar to AS with a safety profile expected to be similar to other approved indications.

Pharmacology:

No clinical pharmacology studies were submitted.

Efficacy

Study M10-791

This was a multicentre, multinational, randomised, double blind, placebo controlled, parallel group study of 40 mg adalimumab fortnightly compared with placebo, self administered subcutaneously for 12 weeks with an open label extension of 144 weeks (data to 68 weeks total has been provided) with 185 patients on 40 mg adalimumab (142 completed to week 68, 55% female, age 19-72 but only 2 subjects >65 years, mean 78kg). Patients were ≥18 years, had active axial spondyloarthritis not fulfilling the modified New York criteria for AS, an inadequate response to, intolerance to or a contraindication to NSAIDs, back pain of at least 3 months, MRI evidence of active inflammatory lesions of the sacroiliac joints or positive HLA-B27 plus some clinical criteria. Patients were excluded if they had AS, psoriasis or psoriatic arthritis, not on a stable DMARD or corticosteroid dose, unstable extra-articular manifestations or recent spinal surgery. Subjects could continue on their stable doses of DMARDs, prednisone, analgesics (except opioids but including tramadol) and/or NSAIDs. Treatment groups were similar at baseline including disease duration, axial SpA related conditions, prior and concomitant treatments (mean 2.9 years
of SpA diagnosis, mean 10 years of SpA symptoms, 48% active inflammatory lesions on MRI of the sacroiliac joint, 78% HLA-B27 positive, 97% inflammatory back pain, 39% elevated CRP, 35% prior DMARD use, 97% prior NSAID use) but there were slightly more patients who were HLA-B27 positive (82% versus 73%) and MRI of the sacroiliac joint positive (51% versus 46%) on adalimumab compared to placebo. 97% completed to Week 12 and 79% completed to Week 68 with the main reasons for discontinuations being adverse event, consent withdrawal and Other. Some 11% of subjects had protocol deviations. The study had 90% power to detect a difference in the primary endpoint.

The primary efficacy endpoint of ASAS40 response at Week 12 using the final analysis set (improvement of ≥40% and absolute improvement of ≥20 units (scale 0-100) from baseline in ≥3 of 4 domains of patient global assessment (VAS score 0-100), total back pain (VAS score 0-100), function (BASFI score 0-100) and inflammation (average of two morning stiffness related BASDAI VAS scores) with no deterioration in the remaining domain) showed superiority of adalimumab compared to placebo of 36.3% versus 14.9%, p<0.001 (ITT 34.7% versus 14.4%, p<0.001). ASAS40 response appeared to be maintained to Week 24 (52%) and Week 68 (67%).

The subgroup analysis showed some patients had greater ASAS40 responses on adalimumab if they were males versus females (52% versus 21%), age <40 years versus >40 years (46% versus 21%), abnormal pooled CRP at baseline versus normal at baseline (55% versus 27%), HLA-B27 positive versus negative (40% versus 19%), concomitant DMARD use at baseline versus none (47% versus 34%), concomitant NSAID use at baseline versus none (39% versus 26%) and <5 years symptom duration versus ≥5 years (49% versus 31%). A history of Inflammatory bowel disease (IBD) or uveitis at screening also had greater ASAS40 responses but the number of subjects was too low. Of these results, an abnormal baseline pooled CRP and <5 years symptom duration were significant findings with age<40 years of borderline significance.

The large number of secondary endpoints supported the efficacy of adalimumab compared with placebo at Week 12 and appeared to be maintained through to Week 68 (or Week 52 for some measures). These included ASAS20, ASAS5/6, Bath Ankylosing Spondylitis disease activity index (BASDAI 50), Short Form-36 Health Status Survey™ Version 2 (SF-36) physical component score and Health Assessment Questionnaire modified for spondyloarthropathies (HAQ) score modified for spondyloarthropathies. However there was no difference in biomarker measures of matrix metalloproteinase-3, type II collagen C-telopeptide or vascular endothelial growth factor A.

Safety

There were 190 patients exposed to adalimumab in the pivotal study of whom 147 were exposed for ≥343 days. Treatment emergent adverse events occurred in 58% on adalimumab versus 59% on placebo with the most common being nasopharyngitis (11.6% versus 3.1%) in the double blind period. Infections occurred in 29.5% of adalimumab subjects compared with 28.9% of placebo subjects (majority being upper respiratory tract infections) and mild injection site reactions occurred in 8.4% versus 3.1%. Nine subjects reported allergic reaction related TEAEs compared with one subject on placebo. Throughout the entire study, the TEAEs occurred in 79.5% of subjects on adalimumab with nasopharyngitis (17.9%) and spondylitis (10.5%) being the most common. There were three serious infections with one of them being tuberculosis. There were no reports of opportunistic infections (excluding TB), lymphomas, malignancies or demyelinating disease. Treatment related TEAEs occurred in 32.6% on adalimumab versus 21.6% on placebo during the double blind period increasing to 45.3% for the entire study with the most common being nasopharyngitis. There were two deaths (suicide and opioid toxicity). Serious adverse events occurred in 3.2% on adalimumab versus 1% on placebo which increased to 10% for the entire study with no clear pattern. Discontinuations occurred in
two adalimumab subjects versus one placebo subject, which increased to 6.3% of subjects for the entire study. Hepatic related events were similar at 4.2% on adalimumab versus 4.1% on placebo and 5.3% on adalimumab for the entire study. There were no significant changes in haematology, chemistry or vital signs.

**Risk management plan**

The Office of Product Review has accepted the Risk Management Plan (RMP) for Adalimumab (edition 10.0, November 2011) with Australian Specific Annex (undated) and recommended further changes to the Australian Specific Annex as outlined below from their report:

- Details of the education program for Australia
- Evaluation of the education program for Australia

The sponsor should address these matters in the Pre Advisory Committee on Prescription Medicines (ACPM) Response and follow up where appropriate with the TGA’s Office of Product Review.

**Risk-benefit analysis**

**Delegate considerations**

**Efficacy**

Adalimumab has demonstrated superiority to placebo in one phase III trial in patients with axSpA over a 12 week period with efficacy appearing to be maintained up to 68 weeks in an open label follow up extension. The primary endpoint (ASAS 40) was a previously validated outcome measure which was developed independent of the development program. The primary endpoint was supported by a large number of secondary endpoints over 12 weeks and maintained for up to 68 weeks. The indication at present is broad and covers all age groups, all grades of disease severity (that is, mild, moderate and severe) and is currently not restricted to patients who have failed other treatments. The pivotal study required patients who were ≥18 years, must have had an inadequate response, intolerance or contraindication to NSAIDs, back pain of at least 3 months, MRI evidence of active inflammatory lesions of the sacroiliac joints or positive HLA-B27 plus some clinical criteria. In Europe, the indication has been restricted to adults with severe disease and diagnostic criteria of objective signs of inflammation by elevated CRP and/or MRI. The indication was also modified to be grouped with the AS indication under a new heading of Axial Spondyloarthritis. Usually diagnostic features are placed in the Clinical Trials section of the PI if the disease is well defined, however, ACPM’s advice on this was requested by the Delegate. Subgroup analysis of the primary endpoint showed that patients with abnormal baseline pooled CRP and <5 years symptom duration had greater responses and these findings were significant for a treatment interaction.

**Safety and RMP**

Adalimumab has demonstrated an acceptable safety profile consistent with that seen for ankylosing spondylitis. The adverse effects profile is expected to be similar to other approved indications for adalimumab. The single pivotal study does however provide limited safety data but the sponsor is continuing this study for an additional 144 weeks of open label treatment and the submission of the final clinical study report will be made a condition of registration. There was a lack of patients over 65 years which the sponsor should address in the PI however the AS data are supportive. Treatment emergent adverse events, serious adverse events and discontinuations due to adverse events were similar to
placebo over the 12 week period with a similar rate of infections but mild injection site adverse events, allergic reactions and nasopharyngitis were more common with adalimumab. There were three serious infections including one case of tuberculosis. No new safety concerns appeared from the data and there were no reports of opportunistic infections (excluding TB), lymphomas, malignancies or demyelinating disease.

**Data deficiencies**

Only two elderly patients were included in the submission and the submitted data were only up to 68 weeks exposure.

**Summary**

Overall at present the submission appears approvable with demonstrated efficacy and an acceptable safety profile. The principal issue is the wording of the indication and whether it should be restricted.

**ACPM’s advice was requested on the following issues:**

1. Is non-radiographic axial spondyloarthritis a disease with consistently defined and agreed diagnostic criteria that supports a new indication?
2. Should the indication be a subset of axial spondyloarthritis and combined with ankylosing spondylitis as in the EU?
3. Should the indication require inclusion of objective signs of inflammation and diagnostic criteria such as MRI and/or CRP or would this be more appropriate in the Clinical Trials section of the PI?
4. Should the indication be restricted to only severe forms of the disease, for use only in adults and for those who have had an inadequate response to or are intolerant of nonsteroidal anti-inflammatory drugs (that is, second line therapy)?

**Delegate’s questions for the sponsor**

The sponsor was asked to address the following issues in the Pre-ACPM response:

1. Discuss the grades of disease severity for patients with nr-axSpA in the pivotal study, that is, mild, moderate and severe and provide an explanation as to why the indication in Europe was restricted to severe patients only.
2. Advise when the next update to the Australian Specific Annex to the RMP will be submitted to the TGA that addresses the matters raised by the RMP evaluator in the second round report.

**Delegate’s recommendation**

The Delegate was inclined to approve this submission by Abbvie Pty Ltd to register Humira (adalimumab) for the new indication of treatment of non-radiographic axial spondyloarthritis based on the quality, safety and efficacy of the product being satisfactorily established for the indication below and for the reasons stated above in the Risk/Benefit Discussion:

**Non-radiographic Axial Spondyloarthritis**

*Humira is indicated for reducing signs and symptoms in adult patients with active axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, who have had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs.*
The indication should include adults and be amended as outlined above to those who have
had an inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs
as per the inclusion criteria of the study, however the wording may require amendments
post ACPM.

**Conditions of registration**

The following are proposed as conditions of registration:

3. The implementation in Australia of the Risk Management Plan (RMP) for Adalimumab (edition 10.0, November 2011) with Australian Specific Annex (undated) and any
   subsequent revisions, as agreed with the TGA.
4. The following studies must be submitted to the TGA, as soon as possible after
completion, for evaluation as a Category 1 submission:
   a. Final study report for M10-791 including the 144 week open label extension.

**Product Information and Consumer Medicine Information**

The evaluator’s recommendations for the PI and CMI should be implemented along with
recommendations to the **Clinical Trials**, **Precautions** section and the **Indications**.

**Consumer Medicine Information (CMI)**

Please provide an updated CMI to incorporate the changes from this submission.

**Response from sponsor**

AbbVie Pty Ltd agreed with the Delegate’s proposed actions as stated above.

The following extract summarises the sponsor’s response to the questions raised in the
Delegate’s Overview.

1. The Delegate suggests the following changes to the PI

   **Indications:**

   - The indication should include adults and be amended as outlined below:

     **Non-radiographic Axial Spondyloarthritis**

     *Humira is indicated for reducing signs and symptoms in adult patients with active axial
     spondyloarthritis without radiographic evidence of ankylosing spondylitis, who have had an
     inadequate response to, or are intolerant to, nonsteroidal anti-inflammatory drugs.*

   **Sponsor response:**

   AbbVie agreed to include the words “adults”, “active”, and “who have had an inadequate
response to, or are intolerant to, nonsteroidal anti-inflammatory drugs” in the indication
wordings.

2. Discuss the grades of disease severity for patients with nr-axSpa in the pivotal
   study, that is, mild, moderate and severe and why the indication in Europe was
   restricted to severe patients only.

   **Sponsor response:**

   Subjects in study M10-791 were required to have a Bath AS Disease Activity Index
   (BASDAI) ≥ 4 at both the Screening and Baseline visits which reflects moderate to severe
disease activity.

   The indication in Europe was limited to severe patients to align with the approved
indication for ankylosing spondylitis.
3. Advise when the next update to the Australian Specific Annex to the RMP will be submitted to the TGA that addresses the matters raised by the RMP evaluator in the second round report.

Sponsor response:

The RMP has been updated and a copy was included with the sponsor’s Pre-ACPM submission.

4. Is non-radiographic axial spondyloarthritis a disease with consistently defined and agreed diagnostic criteria that supports a new indication?

Sponsor response:

The sponsor believes that non-radiographic axial spondyloarthritis is a disease with consistently defined and agreed diagnostic criteria that supports a new indication.

Background to axial spondyloarthritis

Spondyloarthritis (SpA) is a group of diseases that share common clinical, radiographic, and genetic features. Included in this group are ankylosing spondylitis (AS), psoriatic arthritis, reactive arthritis, enteropathic or inflammatory bowel disease (IBD)-related arthritis, and undifferentiated SpA. Among these inflammatory diseases, there is an overlap of signs and symptoms. When evaluating patients for a diagnosis of SpA, a useful distinction that rheumatologists usually make is to first determine if patients have either predominantly axial or predominantly peripheral manifestations; the main reason being that the treatment should be directed to the most important manifestation.

Axial SpA (axSpA) is a chronic inflammatory disease that primarily affects the axial skeleton (the sacroiliac [SI] joints and spine). Patients diagnosed with axSpA can be distinguished from those who may have non-inflammatory causes of back pain based on a combination of any of the following signs and symptoms: the characteristics of the back pain (that is, worsening with rest and improvement with exercise suggest inflammatory back pain); accompanying peripheral (that is, enthesitis, arthritis, dactylitis) and extra-articular manifestations (that is, uveitis, IBD, psoriasis); the presence of the genetic marker human leukocyte antigen (HLA)-B27; the presence of signs of inflammation in the lab (that is, C-reactive protein [CRP], erythrocyte sedimentation rate [ESR]); imaging evidence of inflammation on MRI of the SI joints, or structural damage on the radiographs of the SI joints.

Historically, patients with axSpA were only identified when there was evidence of structural damage of the SI joints on the radiographs (radiographic sacroiliitis, as determined by the modified New York [mNY] criteria) and such patients were diagnosed as having AS. Advances in the knowledge of axSpA has led to the understanding that some patients who have the clinical manifestations typical of this disease may not have evidence of radiographic sacroiliitis at presentation and such patients are now diagnosed as having non-radiographic axSpA (nr-axSpA). Therefore, both AS and nr-axSpA represent the spectrum of axSpA, with the presence or absence of radiographic sacroiliitis as the only differentiating clinical feature.

Using radiographs to make a diagnosis of axial SpA presents several challenges. Radiographs detect sacroiliitis in the form of structural damage but not inflammation.

---

thereby causing a delay in diagnosis for patients with axSpA without radiographic sacroiliitis (nr-axSpA).9

There is also variability in how radiographs are interpreted for the presence of radiographic sacroiliitis.10 With the advent of magnetic resonance imaging (MRI) it is now possible to visualise acute inflammatory lesions that can be highly suggestive of axial SpA in addition to structural changes.11 The ability to detect acute inflammation in the axial skeleton by MRI is one way to facilitate a diagnosis of axial SpA, especially in patients with nr-axSpA, whose radiographs are negative or inconclusive for sacroiliitis.

Rationale for the development of the ASAS criteria

There is, on average, a delay of 5-10 years from the onset of symptoms to the diagnosis of AS using the mNY criteria.7,12,13

It is well established that the development of radiographic sacroiliitis on plain radiographs reflecting structural damage in the SI joints (erosions, sclerosis, ankylosis, joint space changes) can take years to develop despite the presence of inflammation in the SI joints5 thereby constituting a major contributor to the delay in diagnosis of AS. Moreover, not all nr-axSpA patients will go on to develop structural damage visible on radiographs and would therefore not progress to AS, though they have a similar burden of disease. A further contributory factor to the late diagnosis of this inflammatory spinal disease is the observation that axSpA accounts for only around 5% of patients with chronic back pain, resulting in a low level of disease awareness among back pain patients and referring health care providers.14

The Assessment of Spondyloarthritis international Society (ASAS) (an international group of experts in SpA from 37 member countries) has developed and validated classification criteria for patients with axSpA.6,11 These criteria were developed to include patients with or without radiographic sacroiliitis by including both plain radiographs and MRI as imaging modalities.6,11 These criteria identify both AS and nr-axSpA patients and therefore enable the conduct of clinical trials for the treatment of the broad axSpA population; including patients with nr-axSpA.6,11

Prior to the ASAS criteria, the Amor and The European Spondyloarthropathy Study Group (ESSG) criteria were used to define the entire group of patients with peripheral and axial manifestations, regardless of the presence or absence of radiographic sacroiliitis.8,11 However, these criteria do not distinguish patients based on predominant spinal inflammation. Furthermore, the Amor and ESSG criteria do not include information on MRI.8,11

Development and validation of the ASAS criteria

In order to provide an internationally accepted classification standard for research studies in patients with axSpA (AS and nr-axSpA), ASAS identified the need to establish new classification criteria. To start this process, candidate criteria for classification were developed in 2004, based mainly on clinical understanding of typical features seen in

---

patients that are suspected to have SpA. This included the evaluation of ‘paper patients’ where clinical information from real patients (with and without axSpA) was provided on paper to ASAS rheumatologists, who are experts in the field of axSpA. The focus of these candidate criteria was on patients with chronic back pain with age at onset <45 years because by the age of 45, approximately 95% of axSpA patients are symptomatic.

As the next step, the candidate criteria were tested (validated) in a prospective study conducted between 2006 and 2008 across 25 centers with an ASAS rheumatologist in 16 countries. Patients included in this validation study had undiagnosed chronic back pain and age of onset <45 years.

ASAS centers included patients presenting at the outpatient clinic consecutively. In these patients (n=649), the diagnosis (of either “axSpA” or “no SpA”) made by the rheumatologists according to his/her expert opinion was used as the gold standard for the validation of these criteria.

For the refinement of the candidate criteria, the ASAS data set was divided into two sets, which allowed the candidate criteria to be refined in the first data set and thereafter validated in the second data set. The results were presented to ASAS members in 2008 and the final set of candidate criteria were voted on by this group.

The finalised ASAS criteria for axSpA are intended to be applied to patients with chronic back pain for ≥3 months with age of onset <45 years. There is an ‘imaging arm’ requiring the presence of sacroiliitis (on radiographs or MRI) in the context of at least one clinical feature, and a ‘clinical arm’ requiring the presence of HLA-B27 plus at least two other SpA features.

The ASAS criteria were found to have a better sensitivity (82.9%) and specificity (84.4%) in the validation study compared with the Amor (69.4% and 78.4%, respectively) and ESSG (70.7% and 63.5%, respectively) criteria. Following their development, the ASAS classification criteria for axSpA have been evaluated in a number of cohort studies with generally similar or better figures for sensitivity and specificity.

The ASAS criteria for axSpA are intended for use primarily as classification criteria for axSpA for clinical trials and other research studies. In this respect, the ASAS classification criteria provide rheumatologists with a framework for evaluating the numerous features of axSpA when considering the diagnosis of this disease in a given patient. In daily practice, rheumatologists make the diagnosis of axSpA based on the ‘pattern recognition’ of typical clinical features which are assessed by detailed history, physical examination and targeted investigations including imaging.

Although the ASAS criteria reflect many important aspects and features of the disease, which are also used for making the diagnosis, they are not meant to be used as diagnostic criteria.

Characteristics of axSpA patients and burden of disease

Population studies from a range of countries report prevalence estimates for AS between 0.1% to 1.4% and for SpA of around 0.3% to 1.9%. Recent data from the US (NHANES 2009-2010) report prevalence figures of 0.9% using the Amor criteria and 1.4% using EESSG, which are similar to RA estimates of 0.5% to 1.0%.

and it has been identified that approximately 70-80% of all SpA patients have axial involvement.\textsuperscript{19, 20, 21}

The proportion of nr-axSpA patients among all axSpA patients ranges between 40% and 60% according to several national and international referral programs, and depends on the duration of back pain.\textsuperscript{17, 22}

Over time some patients will progress from nr-axSpA to AS. The rate of progression from nr-axSpA to AS (the development of definite radiographic sacroiliitis) is approximately 10% after 2 years and up to 60% after 10 years across studies.\textsuperscript{8} Given this, it is clear that not all axSpA patients will develop definite radiographic sacroiliitis.

Duration of back pain is one of the predictors for the development of AS in patients with nraxSpA; however other factors can act as predictors for progression in axSpA. Elevated CRP over time is a significant predictor for the development of radiographic sacroiliitis, as it is estimated that 25% of patients with nr-axSpA and elevated CRP levels will develop evidence of sacroiliitis on radiographs within 2 years.\textsuperscript{8} In addition, a study from Leeds, UK found that extended inflammation on MRI (sacroiliitis) predicted the development of radiographic sacroiliitis 8 years later.\textsuperscript{23}

Data from registries and randomized controlled studies indicate that patients with axSpA are often in their 30s or 40s\textsuperscript{10, 24, 25} and suffer from substantial axial pain, fatigue, morning stiffness and functional impairment.\textsuperscript{10, 17, 25, 26, 27} The impact of these manifestations is assessed by the Bath Ankylosing Spondylitis Disease Activity Index and Functional Index (BASDAI and BASFI), visual analogue scale measurements of total pain/back pain, and global assessments of disease activity (patient and physician).\textsuperscript{28}

Stiffness, pain, and fatigue have been found to adversely influence quality of life and physical functioning among patients with axSpA.\textsuperscript{29, 30} Furthermore, in these patients, increased disease activity, functional disability and fatigue severity have been found to be

\textsuperscript{18} NHANES= National Health and Nutrition Examination Survey
\textsuperscript{29} Boonen A, van der Linden SM. The burden of ankylosing spondylitis. J Rheumatol Suppl 2006;78:4-11.
associated with poorer mental health status. Poor health-related quality of life may be evidenced by decreased physical function and impaired work outcomes in these relatively young patients. There is evidence that the disease incurs a substantial economic impact on society or patients, with costs driven mainly by the loss of capacity to work.

Axial SpA has a deleterious effect on patients regardless of the presence (AS) or absence (nraxSpA) of evidence of sacroiliitis on radiographs.

Several studies have identified that the burden of subjective symptoms (for example, pain, perceived disease activity, fatigue) is comparable in nr-axSpA and AS patients although spinal mobility and functional status (BASFI) are usually somewhat worse in AS than in nraxSpA due to the presence of structural damage in the former patient group.

Appropriateness of the ASAS criteria for classifying a patient group with limited treatment options in Australia

Application of the ASAS criteria in recent clinical trials has not only provided further validation for the concept of axSpA but has also demonstrated that patients from across the broad axSpA population, not just those with radiographic evidence of sacroiliitis, can derive benefit from proactive treatment of the signs and symptoms of active inflammatory disease.

Axial SpA patients have been recognised for a long time in clinical practice (although by different nomenclature) and so the ASAS criteria are not defining or describing a new group of SpA patients, but are instead improving the classification of these patients.

References:
Within Australia, nonsteroidal anti-inflammatory drugs (NSAIDs) and physical therapy are the initial treatments of choice in this setting\(^{43}\), however, for those patients with nr-axSpA who are intolerant of or not adequately controlled by NSAIDs or in whom NSAIDs are contraindicated, limited treatment options exist. This highlights a need for clinical trials that could provide new therapies to improve patient health given that nr-axSpA patients exhibit comparable levels of disease activity and burden to those with AS. Recognition of active axSpA (AS and nr-axSpA) as an indication, regardless of evidence of sacroiliitis on radiographs, could therefore enable the application of appropriate and effective treatment strategies to better address patient needs.

Regardless of whether early and effective therapy affects disease progression or structural damage, appropriate treatment enables patients to have a better quality of life with less pain and less consequences of back pain such as reduced work productivity.\(^{17, 26, 27, 39, 44}\)

**5. Should the indication be a subset of axial spondyloarthritis and combined with ankylosing spondylitis as in the EU?**

**Sponsor response:**

As noted above, both ankylosing spondylitis and non-radiographic axial spondyloarthritis represent the spectrum of axial spondyloarthritis, with the presence or absence of radiographic sacroiliitis as the only differentiating clinical feature. Therefore, the sponsor considers that is appropriate for the proposed indication to be a subset of axial spondyloarthritis and combined with ankylosing spondylitis as in the EU.

**Advisory committee considerations**

The sponsor’s application was not considered by the Advisory Committee on Prescription Medicines.

**Outcome**

Following discussion with the sponsor regarding concerns over the validity of the data and the need for re-analysis, the sponsor withdrew their submission on 19 August 2013, before a decision had been made by the TGA.

**Attachment 1. Product Information**

The Product Information approved at the time this AusPAR was published is at Attachment 1. For the most recent Product Information please refer to the TGA website at [http://www.tga.gov.au/hp/information-medicines-pi.htm](http://www.tga.gov.au/hp/information-medicines-pi.htm).

**Attachment 2. Extract from the Clinical Evaluation Report**

---

